Hospital hep c treatment aims to cure drug users
NCT ID NCT03981211
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested giving hepatitis C treatment to people who inject drugs while they were already in the hospital for other infections. The goal was to cure their hepatitis C and make sure they stayed connected to care afterward. The study was stopped early, but it included 21 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
21 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Sep 2025
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible to participate in this study. 1. Have voluntarily signed the informed consent form. 2. 18 years of age or older. 3. Injected drugs within the last 6 months 4. Hospitalised with an IRID with an anticipated inpatient stay of \> 1 week Participants must meet the following additional inclusion criteria to be treated in this study. 5. HCV RNA positive 6. Compensated liver disease 7. Documented non-cirrhotic at enrolment with a qualifying liver FibroScan ≤ 9.5 kpA 8. If co-infection with HIV is documented, the subject must meet the following criteria: 1. ART naïve with CD4 T cell count \>500 cells/mm3; OR 2. On a stable ART regimen (containing only permissible ART) for \>4 weeks prior to screening visit, with CD4 T cell count ≥200 cells/mm3 and a plasma HIV RNA level below the limit of detection. Exclusion Criteria: Participants who meet any of the exclusion criteria are not to be enrolled in this study. 1. Inability or unwillingness to provide informed consent or abide by the requirements of the study 2. Actively intoxicated. Participants that meet any of the additional exclusion criteria are not to be treated in this study. 3. History of any of the following: b. Clinical hepatic compensation (i.e. ascites, encephalopathy or variceal haemorrhage) c. Solid organ transplant d. History of severe, life-threatening or other significant sensitivity to study drugs (glecaprevir/pibrentasvir/sofosbuvir) or any excipients of the study drugs 4. Creatinine clearance (CLcr) \< 30 mL/min at screening (Cohort B only) 5. Pregnant or nursing female 6. Decompensated liver disease 7. Use of prohibited concomitant medications 8. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent \> 10 mg/day for \>2 weeks) 9. Prior treatment failure with an NS5A based DAA regimen Patients without an IRID but who fulfill all other criteria and are admitted with an expected duration of stay \> 1 week may also be included at discretion of study team.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hepatitis C are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blacktown Mt Druitt Hospital
Sydney, New South Wales, 2148, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
St Vincent's Hospital
Melbourne, Victoria, 3065, Australia
-
St Vincent's Hospital Sydney
Sydney, New South Wales, 2010, Australia
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home hepatitis c tests reach people clinics miss?
- Home hepatitis c tests could reach thousands in pakistan
- Mailing hepatitis c tests home could reach people who avoid clinics
- Hospitals could screen every patient for hepatitis c
- Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
- Home test kits could transform STI screening for sex workers